1. Clinical Recognition and Treatment of Levodopa-Induced Dyskinesia

3. Levodopa-Induced Dyskinesia Introduction

4. Prevalence of Dyskinesia

5. Videos: Disordered Movement Types

6. Fluctuations in Dopamine Levels

7. Dysregulation of Dopamine Leading to the Development of Dyskinesia

8. Effects of AEs on Patient Quality of Life

9. Patient-Rated Impairment in Quality of Life

10. Rating Scales Used to Assess Dyskinesia

11. Approaches to Levodopa-Induced Dyskinesia Management

12. Amantadine IR

13. Amantadine ER Overview of Clinical Studies

14. Primary Endpoint: UDysRS Results Over Time EASE LID and EASE LID 3

15. Key Secondary Endpoints: Home Diary Data EASE LID and EASE LID 3

16. Most Common AEs and Reasons for Treatment Discontinuation Amantadine ER

17. Additional Approaches

18. Concluding Remarks

19. Abbreviations